Quick turn

In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase I study of an undisclosed program. At that point, new investor Biogen Idec Inc. (NASDAQ:BIIB) can exercise an option to acquire the ataxia company.